These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 24326984)

  • 1. Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer.
    Inanc M; Ozkan M; Karaca H; Berk V; Bozkurt O; Duran AO; Ozaslan E; Akgun H; Tekelioglu F; Elmali F
    Med Oncol; 2014 Jan; 31(1):801. PubMed ID: 24326984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
    Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
    Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer.
    Ren X; Yuan L; Shen S; Wu H; Lu J; Liang Z
    Tumour Biol; 2016 Aug; 37(8):11385-95. PubMed ID: 26968553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of EGFR and cytokeratin 5/6 immunohistochemical expression in triple-negative breast cancer.
    Abdelrahman AE; Rashed HE; Abdelgawad M; Abdelhamid MI
    Ann Diagn Pathol; 2017 Jun; 28():43-53. PubMed ID: 28648939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression of CK5/6 and CK17 and its correlation with prognosis of triple-negative breast cancer patients].
    Liu ZB; Wu J; Ping B; Feng LQ; Shen ZZ; Shao ZM
    Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):610-4. PubMed ID: 19102940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple-negative breast cancer: immunohistochemical correlation with basaloid markers and prognostic value of survivin.
    Dogu GG; Ozkan M; Ozturk F; Dikilitas M; Er O; Ozturk A
    Med Oncol; 2010 Mar; 27(1):34-9. PubMed ID: 19156550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.
    Yue Y; Astvatsaturyan K; Cui X; Zhang X; Fraass B; Bose S
    PLoS One; 2016; 11(3):e0149661. PubMed ID: 26930401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Basal cytokeratin expression in relation to immunohistochemical and clinical characterization in breast cancer patients with triple negative phenotype.
    Liu ZB; Wu J; Ping B; Feng LQ; Di GH; Lu JS; Shen KW; Shen ZZ; Shaol ZM
    Tumori; 2009; 95(1):53-62. PubMed ID: 19366057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and Clinical Significance of Claudin-7, PDL-1, PTEN, c-Kit, c-Met, c-Myc, ALK, CK5/6, CK17, p53, EGFR, Ki67, p63 in Triple-negative Breast Cancer-A Single Centre Prospective Observational Study.
    Constantinou C; Papadopoulos S; Karyda E; Alexopoulos A; Agnanti N; Batistatou A; Harisis H
    In Vivo; 2018; 32(2):303-311. PubMed ID: 29475913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.
    Zhang M; Zhang X; Zhao S; Wang Y; Di W; Zhao G; Yang M; Zhang Q
    Target Oncol; 2014 Dec; 9(4):349-57. PubMed ID: 24233638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of PTEN expression is associated with aggressive behavior and poor prognosis in Middle Eastern triple-negative breast cancer.
    Beg S; Siraj AK; Prabhakaran S; Jehan Z; Ajarim D; Al-Dayel F; Tulbah A; Al-Kuraya KS
    Breast Cancer Res Treat; 2015 Jun; 151(3):541-53. PubMed ID: 25981902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1.
    Pintens S; Neven P; Drijkoningen M; Van Belle V; Moerman P; Christiaens MR; Smeets A; Wildiers H; Vanden Bempt I
    J Clin Pathol; 2009 Jul; 62(7):624-8. PubMed ID: 19561231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor expression is a favorable prognostic factor in triple-negative breast cancers.
    Zuo T; Wilson P; Cicek AF; Harigopal M
    Hum Pathol; 2018 Oct; 80():239-245. PubMed ID: 29902579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of PTEN expression is associated with IGFBP2 expression, younger age, and late stage in triple-negative breast cancer.
    Dean SJ; Perks CM; Holly JM; Bhoo-Pathy N; Looi LM; Mohammed NA; Mun KS; Teo SH; Koobotse MO; Yip CH; Rhodes A
    Am J Clin Pathol; 2014 Mar; 141(3):323-33. PubMed ID: 24515759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of PTEN in high grade advanced stage triple negative breast ductal cancers in African American women.
    Khan F; Esnakula A; Ricks-Santi LJ; Zafar R; Kanaan Y; Naab T
    Pathol Res Pract; 2018 May; 214(5):673-678. PubMed ID: 29653745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].
    Liu H; Fan QH; Zhang ZH; Li X; Yu HP; Liu GZ; Meng FQ
    Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):23-8. PubMed ID: 19489221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.
    Cheang MC; Voduc D; Bajdik C; Leung S; McKinney S; Chia SK; Perou CM; Nielsen TO
    Clin Cancer Res; 2008 Mar; 14(5):1368-76. PubMed ID: 18316557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin growth factor receptor-1 expression and loss of PTEN protein predict early recurrence in triple-negative breast cancer.
    Iqbal J; Thike AA; Cheok PY; Tse GM; Tan PH
    Histopathology; 2012 Oct; 61(4):652-9. PubMed ID: 22759273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.
    Nassar A; Sussman ZM; Lawson D; Cohen C
    Breast J; 2012 Sep; 18(5):399-405. PubMed ID: 22882580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A CLDN1-negative phenotype predicts poor prognosis in triple-negative breast cancer.
    Ma F; Ding X; Fan Y; Ying J; Zheng S; Lu N; Xu B
    PLoS One; 2014; 9(11):e112765. PubMed ID: 25393310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.